

Efficacy and Mechanism Evaluation Programme

19/136 Evaluating interventions for the diagnosis and treatment of Autoimmune Diseases

Closing date: 1:00 pm, 16 April 2020 (two stage – Stage 1 to Stage 2)

Applications are sought for research to evaluate interventions for the diagnosis, treatment, monitoring or management of patients with autoimmune disease(s).

The programme would like to build on its existing portfolio by encouraging applications that utilise novel or efficient study designs, for example to evaluate the use of a single intervention across multiple diseases, or the use of multiple interventions in one disease. Innovative trial designs are therefore encouraged but not essential. Applicants will need to fully justify their choice of study design.

Areas of interest include, but are not limited to:

- repurposing of existing interventions, e.g. pharmaceuticals, cell therapies, diagnostics;
- evaluation of biomarkers used for diagnosis, to guide treatment, to monitor treatment response or to predict relapse/remission.

Biomarker validation studies are within the scope of this call but the discovery of novel biomarkers is excluded.

The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland, Health and Care Research in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton.

Efficacy and Mechanism Evaluation Programme, National Institute for Health Research
Evaluation, Trials and Studies Coordinating Centre, University of Southampton,
Alpha House, Enterprise Road, Southampton, SO16 7NS

email: eme@nihr.ac.uk

web: www.nihr.ac.uk/eme

tel: +44(0)23 8059 4303